Veverimer

Active substance
Veverimer
Domain
Metabolism and Endocrinology
Reason of inclusion in Horizonscan Geneesmiddelen
New medicine (specialité)
Main indication
Metabolic diseases
Extended indication
Metabolic Acidosis Associated With Chronic Kidney Disease

1. Product

Manufacturer
Tricida
Mechanism of action
Other
Route of administration
Oral
Therapeutical formulation
Oral suspension
Budgetting framework
Extramural (GVS)
Additional comments
Veverimer (TRC101) is a non-absorbed polymer that is designed to bind hydrochloric acid in the GI tract and remove it from the body through excretion in the feces.

2. Registration

Registration route
Centralised (EMA)
Submission date
2020
Expected Registration
2021
Orphan drug
No
Registration phase
Clinical trials

3. Therapeutic value

Current treatment options
Bicarbonaat
Therapeutic value
Potential added value
Substantiation
Mogelijke meerwaarde verwacht ten opzichte van huidige behandelopties.
Frequency of administration
1 times a day
References
NCT03317444

4. Expected patient volume per year

Patient volume

> 10,000

Market share is generally not included unless otherwise stated.

References
Nierstichting; Ortega and Arora. Nefrologia. 2012;32(6):724-30
Additional comments
Ruim 10% (1,7 miljoen mensen) van de Nederlandse bevolking heeft chronische nierschade. 40% (680.000 mensen) daarvan weet dat niet. Klachten ontstaan vaak pas als de nierfunctie nog maar 30% is. Hiervan heeft mogelijk 1-2% metabole acidose. Het gaat hier dus mogelijk om meer dan 10.000 patiënten. Het is momenteel onduidelijk of TRC101 behandeling van deze groep geheel gaat vervangen maar dat risico is wel reëel.

5. Expected cost per patient per year

There is currently nothing known about the expected cost.

6. Potential total cost per year

There is currently nothing known about the possible total cost.

7. Off label use

There is currently nothing known about off label use.

8. Indication extension

Indication extension
No

9. Other information

There is currently no futher information available.